Dicot Pharma
Dicot Pharma is a Swedish clinical-stage pharmaceutical company focused on developing LIB-01, a novel treatment candidate for erectile dysfunction. The company’s work centers on drug discovery, clinical development, and intellectual property protection for a global sexual-health market.
Fiscal year 2025 · change from previous year
Development 2023–2025
Business
Share of revenueDevelopment of LIB-01 through preclinical and clinical stages.
Patent families, know-how, and related protection of the LIB-01 platform.
Potential upfront, milestone, and royalty economics from licensing or partnering.
Customers
Dicot Pharma does not yet sell a commercial product; its near-term counterparties are clinical trial sites, contract manufacturers, and research partners that support development of LIB-01. Longer term, the company’s commercial customers would be patients and prescribing physicians in the erectile dysfunction market, with value created through outlicensing or partnering with a pharmaceutical commercializer.
Trial sites, investigators, and CRO-type partners that execute phase studies for LIB-01.
Specialized pharmaceutical manufacturers that produce study drug and placebo tablets.
Potential industrial partners that could outlicense development and commercialization rights.
Men treated for erectile dysfunction and the physicians who prescribe the eventual product.
Equity investors and warrant holders financing the clinical development program.
Strategy
Dicot Pharma’s strategy is to advance LIB-01 through clinical development and use data to support partnering or outlicensing. The company also seeks to broaden its pipeline over time, while protecting its intellectual property and preserving flexibility through external financing and industrial collaborations.
Clinical data are the main value driver for a precommercial biotech and determine partnering potential.
Partnerships can fund development and convert clinical progress into non-dilutive economics.
Patent and know-how protection are essential to preserve exclusivity and bargaining power.
Additional indications or assets could reduce single-asset dependence and expand long-term value.
Geography
Dicot Pharma is headquartered in Sweden and develops LIB-01 for a global market. Its clinical work has involved multiple sites across three countries, while manufacturing and development partnerships are international in scope.
Risks
Dicot Pharma’s main risks are typical of a single-asset clinical biotech: clinical failure, funding needs, and dependence on key personnel. The company also faces intellectual property, manufacturing, and partnering risks because its value depends on protecting LIB-01 and converting development progress into a commercial agreement.
- Clinical development riskImpact: CriticalLikelihood: High
LIB-01 is still in development, so efficacy, safety, and trial design outcomes remain uncertain.
Exposure: Phase 2 and later-stage studies
- Capital requirementsImpact: HighLikelihood: High
A precommercial biotech typically consumes cash before any product revenue is generated.
Exposure: Financing of ongoing and future trials
- Key personnel dependenceImpact: HighLikelihood: Medium
The business relies heavily on management, board members, and specialized scientific expertise.
Exposure - Intellectual property protectionImpact: HighLikelihood: Low
Competitors may challenge patents or develop alternative compounds and know-how.
Exposure: LIB-01 exclusivity and partnering leverage
- Partnering and commercialization riskImpact: MediumLikelihood: Medium
Future value depends on securing industrial partners on acceptable terms.
Exposure: Outlicensing and royalty economics
Accounting
Judgemental itemsClinical and project spending is recognized immediately, which suppresses asset balances and increases period expense.
Impact: No capitalized development asset or future amortization from current projects
Study costs are concentrated when patients are enrolled and drugs are used, creating uneven quarterly results.
Impact: Comparability between quarters is limited
Employee option programs create non-cash expense recognized over vesting periods.
Impact: Affects operating expenses and equity
Funding rounds and warrant exercises affect share count and cash resources.
Impact: Dilution and financing capacity
Similar listed companies
Publicly listed companies with a comparable business focus.
Vicore Pharma Holding AB
VCRE · Pharmaceutical Preparations
Vicore Pharma Holding AB is a Swedish pharmaceutical development company focused on research and development of drug candidates for severe respiratory and fibrotic diseases.
Swedish Orphan Biovitrum
SOBI · Health Care
Swedish Orphan Biovitrum AB (Sobi) is a global biopharmaceutical company dedicated to transforming the lives of individuals with rare and debilitating diseases.
Capricor Therapeutics, Inc
CAPR · Pharmaceutical Preparations
Cinclus Pharma Holding
CINPHA · Health Care
Cinclus Pharma Holding AB is a Swedish pharmaceutical company focused on developing and commercializing innovative treatments for gastroesophageal reflux disease (GERD).
IRLAB Therapeutics
IRLAB-A · Health Care
IRLAB Therapeutics is a Swedish biopharmaceutical company focused on discovering and developing novel treatments for Parkinson's disease and other central nervous system (CNS) disorders.
SynAct Pharma
SYNACT · Health Care
SynAct Pharma AB is a clinical stage biotechnology company based in Lund, Sweden, specializing in the resolution of inflammation through the selective activation of the melanocortin system.
Last updated: 24/09/2026